Classification and toxicities of vascular disrupting agents

Clinical Lung Cancer

Volumn 12, Issue 1, 2011, Pages 18-25

  Hasani, Arman ^a   Leighl, Natasha ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

ASA404; AVE8062; CA4P; ZD6126

Indexed keywords

AMLODIPINE; ATENOLOL; BEVACIZUMAB; BNC 105P; CARBOPLATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; CYT 997; DILTIAZEM; DOCETAXEL; GLYCERYL TRINITRATE; HEART ENZYME; METOPROLOL; MITOFLAXONE; MPC 6827A; N ACETYLCOLCHINOL PHOSPHATE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NIFEDIPINE; OMBRABULIN; PACLITAXEL; PLINABULIN; SOBLIDOTIN; TUBULIN; UNCLASSIFIED DRUG; VADIMEZAN; VASCULAR TARGETING AGENT;

ABDOMINAL PAIN; ADVANCED CANCER; ANGINA PECTORIS; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ATAXIA; BACKACHE; BLEEDING; BLOOD TOXICITY; BLURRED VISION; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CEREBELLAR ATAXIA; COLOR DISCRIMINATION; COLORECTAL CANCER; CONFUSION; CONSTIPATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG STRUCTURE; DYSPHASIA; DYSPNEA; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEADACHE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; ILEUS; INFECTION; INJECTION SITE PAIN; KIDNEY CARCINOMA; LEUKEMIA; LIMB WEAKNESS; LUNG NON SMALL CELL CANCER; MALAISE; MELANOMA; MOTOR NEURON DISEASE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE NECROSIS; NAUSEA AND VOMITING; NEUROBLASTOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PAIN; PARESTHESIA; PERINEAL PARESTHESIA; PERIPHERAL NEUROPATHY; PERIRECTAL PARESTHESIA; PLEURA MESOTHELIOMA; PROSTATE CANCER; PRURITUS; QT PROLONGATION; RESTLESSNESS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SARCOMA; SENSORY NEUROPATHY; SEROTININ RELEASE SYNDROME; SIDE EFFECT; SLURRED SPEECH; SOFT TISSUE SARCOMA; SOLID TUMOR; SWEATING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; THYROID CANCER; TREMOR; TUMOR PAIN; URINE INCONTINENCE; VISUAL DISORDER;

EID: 79551570717     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.3816/CLC.2011.n.002     Document Type: Review

References (49)

1. Hinnen P, Eskens F. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-65.
2. Siemann D, Horsman M. Vascular targeted therapies in oncology. Cell Tissue Res 2009;335:241-8.
3. Thorpe P. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
4. Kerr D, Kaye S, Graham J, et al. Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester). Cancer Res 1986;46:3142-6.
5. Kerr D, Kaye S, Cassidy J, et al. Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 1987;47:6776-81.
6. Zhou S, Kestell P, Baguley B, et al. 5, 6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Invest New Drugs 2002;20:281-95.
7. Kerr D, Maughan T, Newlands E, et al. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 1989;60:104-6.
8. Rewcastle G, Atwell G, Li Z, et al. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 1991;34:217-22.
9. Baguley B. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8.
10. McKeage M, Fong P, Jeffery M, et al. 5, 6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res 2006;12:1776-84.
11. Roberts Z, Ching L, Vogel S. IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid (DMXAA). J Interferon Cytokine Res 2008;28:133-9.
12. Jassar A, Suzuki E, Kapoor V, et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005;65:11752-61.
13. Lee RM, Gewirtz DA. Colchicine site inhibitors of microtubule integrity as vascular disrupting agents. Drug Dev Res 2008;69:352-8.
14. Dark G, Hill S, Prise V, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
15. Griggs J, Hesketh R, Smith G, et al. Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br J Cancer 2001;84:832-5.
16. Hoekstra R, Verweij J, Eskens F. Clinical trial design for target specific anticancer agents. Invest New Drugs 2003;21:243-50.
17. Krohn K, Link J, Mason R. Molecular imaging of hypoxia. J Nucl Med 2008;49(suppl 2):129S-48S.
18. Galbraith S, Maxwell R, Lodge M, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
19. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and trans-lational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
20. Galbraith S, Rustin G, Lodge M, et al. Effects of 5, 6- dimethylxanthenone-4-ace-tic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
21. Stevenson J, Rosen M, Sun W, et al. Phase I trial of the antivascular agent com-bretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38.
22. Evelhoch J, LoRusso P, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-7.
23. Delmonte A, Sessa C. AVE8062: a new combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 2009;18:1541-8.
24. Akerley WL, Schabel M, Morrell G, et al. A randomised phase 2 trial of combre-tastatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies.). J Clin Oncol 2007;25(18 suppl): 616s (abstract 14060).
25. Rustin G, Galbraith S, Anderson H, et al. Phase I clinical trial of weekly combre-tastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22.
26. LoRusso PM, Gadgeel SM, Wozniak A, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26:159-67.
27. Nathan PD, Judson I, Padhani A, et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(20 suppl): 165s (abstract 3550).
28. Desai J, Wong S, Chong G, et al. Phase I, pharmacokinetic, and pharmacody-namic evaluation of BNC105P, a novel anticancer agent that is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation. J Clin Oncol 2009;27(15 suppl): (abstract e14512).
29. O'Connor J, Jackson A, Parker G, et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007;96:189-95.
30. Siim BG, Lee A, Shalal-Zwain S, et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5, 6-dimethylxanthe-none-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52.
31. Jameson MB, Thompson P, Baguley B, et al. Clinical aspects of a phase I trial of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-50.
32. Kestell P, Paxton J, Rewcastle G, et al. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5, 6-dimethylxanthenone-4- acetic acid in the mouse, rat and rabbit. Cancer Chemother Pharmacol 1999;43:323-30.
33. Rustin G, Bradley C, Galbraith S, et al. 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 2003;88:1160-7.
34. Laties A, Zrenner E. Viagra (sildenafil citrate) and ophthalmology. Prog Retin Eye Res 2002;21:485-506.
35. McKeage M, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 2008;99:2006-12.
36. McKeage M, Reck M, Jameson M, et al. Phase II study of ASA404 (vadimezan, 5, 6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m (2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-7.
37. AACR.org. [Web site]. Available at http://www.aacr.org/home/public-media/ aacr-press-releases.aspx?d=1731. Accessed: March 15, 2010.
38. Cooney M, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:96-100.
39. Ke Q, Bodyak N, Rigor D, et al. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats. Vascul Pharmacol 2009;51:337-43.
40. Tozer G, Prise V, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59:1626-34.
41. Zweifel M, Jayson G, Reed N, et al. Combretastatin A-4 phosphate (CA4P) car-boplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results. J Clin Oncol 2009;27: (15 suppl): 277s (abstract 5502).
42. Bilenker J, Flaherty K, Rosen M, et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005;11:1527-33.
43. Rustin GJ, Nathan PD, Boxall J, et al. A phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer. J Clin Oncol 2005;23: (16 suppl): 217s (abstract 3103).
44. Beerepoot L, Radema S, Witteveen E, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24:1491-8.
45. Gould S, Westwood F, Curwen J, et al. Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats. J Natl Cancer Inst 2007;99:1724-8.
46. Sessa C, Soria JC, Tolcher A, et al. A phase I pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients (pts) with advanced solid tumors - preliminary results. Ann Oncol 2009;20(S3): iii24 (Meeting Abstracts).
47. Hande K, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006;12:2834-40.
48. Mauer A, Cohen E, Ma P, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:631-6.
49. Michels J, Ellard S, Le L, et al. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol 2010;21:305-11.